$JAGX
Jaguar Health, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022003435 Filed on March 11, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $2.080M $4.335M $2.580M
YoY Change -19.38% -53.83% 70.86%
Cost Of Revenue $469.0K $2.333M $790.0K
YoY Change -40.63% -28.87% 6.76%
Gross Profit $1.611M $2.002M $1.790M
YoY Change -10.0% -67.23% 135.53%
Gross Profit Margin 77.45% 46.18% 69.38%
Selling, General & Admin $6.951M $26.00M $5.050M
YoY Change 37.64% 23.82% -2.7%
% of Gross Profit 431.47% 1298.55% 282.12%
Research & Development $5.482M $15.08M $1.900M
YoY Change 188.53% 135.13% 36.69%
% of Gross Profit 340.29% 753.2% 106.15%
Depreciation & Amortization $429.0K $1.719M $430.0K
YoY Change -0.23% -0.46% -2.27%
% of Gross Profit 26.63% 85.86% 24.02%
Operating Expenses $12.43M $41.08M $6.960M
YoY Change 78.64% 49.86% 5.78%
Operating Profit -$10.82M -$40.71M -$5.170M
YoY Change 109.32% 52.77% -11.17%
Interest Expense -$2.747M $8.421M -$1.740M
YoY Change 57.87% 201.61% 923.53%
% of Operating Profit
Other Income/Expense, Net -$749.0K -$765.0K $0.00
YoY Change -502.63% -100.0%
Pretax Income -$14.32M -$52.60M -$8.770M
YoY Change 63.26% 55.58% 47.15%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.31M -$52.60M -$8.770M
YoY Change 63.2% 55.58% 47.15%
Net Earnings / Revenue -688.13% -1213.38% -339.92%
Basic Earnings Per Share -$1.18
Diluted Earnings Per Share -$308.9K -$1.18 -$116.7K
COMMON SHARES
Basic Shares Outstanding 44.71M
Diluted Shares Outstanding 44.71M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.05M $17.05M $8.090M
YoY Change 110.77% 110.77% 131.14%
Cash & Equivalents $17.05M $8.090M
Short-Term Investments
Other Short-Term Assets $4.339M $4.339M $2.360M
YoY Change 83.86% 83.86% 7.27%
Inventory $4.900M $4.900M $2.782M
Prepaid Expenses
Receivables $1.709M $1.709M $2.098M
Other Receivables $435.0K $435.0K $28.00K
Total Short-Term Assets $28.43M $28.43M $17.79M
YoY Change 59.81% 59.83% 86.89%
LONG-TERM ASSETS
Property, Plant & Equipment $650.0K $1.734M $677.0K
YoY Change -3.99% 155.0% -4.65%
Goodwill
YoY Change
Intangibles $22.65M $24.34M
YoY Change -6.93%
Long-Term Investments
YoY Change
Other Assets $446.0K $446.0K $40.00K
YoY Change 1015.0% 1015.0% -73.33%
Total Long-Term Assets $24.83M $24.83M $25.05M
YoY Change -0.88% -0.87% -6.84%
TOTAL ASSETS
Total Short-Term Assets $28.43M $28.43M $17.79M
Total Long-Term Assets $24.83M $24.83M $25.05M
Total Assets $53.27M $53.27M $42.84M
YoY Change 24.33% 24.33% 17.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.929M $4.929M $4.759M
YoY Change 3.57% 3.55% -11.05%
Accrued Expenses $7.117M $7.357M $4.493M
YoY Change 58.4% 63.85% 37.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.184M $3.184M $3.790M
YoY Change -15.99% -15.99% -44.1%
Total Short-Term Liabilities $15.47M $15.47M $13.22M
YoY Change 17.03% 17.03% -14.1%
LONG-TERM LIABILITIES
Long-Term Debt $25.02M $25.02M $12.42M
YoY Change 101.47% 101.47% 2660.0%
Other Long-Term Liabilities $919.0K $919.0K
YoY Change
Total Long-Term Liabilities $25.94M $25.94M $12.42M
YoY Change 108.86% 108.86% 2660.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.47M $15.47M $13.22M
Total Long-Term Liabilities $25.94M $25.94M $12.42M
Total Liabilities $41.41M $41.65M $25.64M
YoY Change 61.51% 62.46% 61.88%
SHAREHOLDERS EQUITY
Retained Earnings -$219.5M -$166.9M
YoY Change 31.51%
Common Stock $231.1M $184.1M
YoY Change 25.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.61M $11.61M $17.20M
YoY Change
Total Liabilities & Shareholders Equity $53.27M $53.27M $42.84M
YoY Change 24.33% 24.33% 17.67%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$14.31M -$52.60M -$8.770M
YoY Change 63.2% 55.58% 47.15%
Depreciation, Depletion And Amortization $429.0K $1.719M $430.0K
YoY Change -0.23% -0.46% -2.27%
Cash From Operating Activities -$8.923M -$34.97M -$4.060M
YoY Change 119.78% 128.89% 29.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $6.000K $0.00
YoY Change -14.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $10.48M -$6.000K $0.00
YoY Change -14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $100.0K
YoY Change -75.37%
Cash From Financing Activities 3.121M 43.94M 10.80M
YoY Change -71.1% 125.41% 118.18%
NET CHANGE
Cash From Operating Activities -8.923M -34.97M -4.060M
Cash From Investing Activities 10.48M -6.000K 0.000
Cash From Financing Activities 3.121M 43.94M 10.80M
Net Change In Cash 4.676M 8.961M 6.740M
YoY Change -30.62% 113.0% 272.38%
FREE CASH FLOW
Cash From Operating Activities -$8.923M -$34.97M -$4.060M
Capital Expenditures $0.00 $6.000K $0.00
Free Cash Flow -$8.923M -$34.98M -$4.060M
YoY Change 119.78% 128.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-52595000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38648000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44711588
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12880868
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44711588
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12880868
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001585608
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2021 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.00
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.33
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
P10Y
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.33
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-52595000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38648000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.00
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36714
CY2021 dei Entity Registrant Name
EntityRegistrantName
JAGUAR HEALTH, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2956775
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Pine Street, Suite 400
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94104
CY2021 dei City Area Code
CityAreaCode
415
CY2021 dei Local Phone Number
LocalPhoneNumber
371-8300
CY2021 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
CY2021 dei Trading Symbol
TradingSymbol
JAGX
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
215622279
CY2021 dei Auditor Name
AuditorName
RBSM, LLP
CY2021 dei Auditor Location
AuditorLocation
Larkspur, California
CY2021 dei Auditor Firm
AuditorFirmId
587
CY2020 dei Auditor Name
AuditorName
Mayer Hoffman McCann P.C.
CY2020 dei Auditor Location
AuditorLocation
San Diego, California
CY2020 dei Auditor Firm
AuditorFirmId
199
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17051000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8090000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1709000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2098000
CY2020Q4 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
2434000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
435000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
28000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4900000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2782000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4339000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2360000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
28434000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4929000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4759000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7117000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4493000
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1000
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
179000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
12421000
CY2021Q4 us-gaap Liabilities
Liabilities
41412000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17792000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1084000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
22651000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24337000
CY2021Q4 us-gaap Other Assets
OtherAssets
446000
CY2020Q4 us-gaap Other Assets
OtherAssets
37000
CY2021Q4 us-gaap Assets
Assets
53265000
CY2020Q4 us-gaap Assets
Assets
42843000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
240000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3184000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3789000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15471000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13220000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
919000
CY2021Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
7800000
CY2020Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
0
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25022000
CY2020Q4 us-gaap Liabilities
Liabilities
25641000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
231100000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
184097000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
242000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219494000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166899000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11853000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17202000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53265000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42843000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
2333000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
3280000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15079000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6413000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8894000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6609000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17103000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14387000
CY2021 jagx Warrants Inducement Expense
WarrantsInducementExpense
1462000
CY2020 jagx Warrants Inducement Expense
WarrantsInducementExpense
3696000
CY2021 jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
CY2020 jagx Convertible Preferred Stock Inducement Expense
ConvertiblePreferredStockInducementExpense
1647000
CY2020 jagx Expense On Modification Of Warrants
ExpenseOnModificationOfWarrants
86000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10673000
CY2020 jagx Stock Issued During Period Redemption Of Convertible Preferred Stock Under Exchange Transaction
StockIssuedDuringPeriodRedemptionOfConvertiblePreferredStockUnderExchangeTransaction
4867000
CY2020 jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
105000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
45043000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
36032000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-40708000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-26647000
CY2021 us-gaap Interest Expense
InterestExpense
8421000
CY2020 us-gaap Interest Expense
InterestExpense
2792000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1864000
CY2021 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
1953000
CY2020 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
2696000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-765000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
190000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52600000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33809000
CY2021 us-gaap Profit Loss
ProfitLoss
-52600000
CY2020 us-gaap Profit Loss
ProfitLoss
-33809000
CY2021 jagx Net Income Loss Available To Common Stockholders And Noncontrolling Interest
NetIncomeLossAvailableToCommonStockholdersAndNoncontrollingInterest
-52600000
CY2020 jagx Net Income Loss Available To Common Stockholders And Noncontrolling Interest
NetIncomeLossAvailableToCommonStockholdersAndNoncontrollingInterest
-38648000
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52595000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38648000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.00
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44711588
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12880868
CY2020 jagx Stock Issued During Period Value To Sagard Capital Exchange For Services
StockIssuedDuringPeriodValueToSagardCapitalExchangeForServices
879000
CY2020 jagx Stock Issued During Period Value Exchange Of Royalty Interest
StockIssuedDuringPeriodValueExchangeOfRoyaltyInterest
256000
CY2020 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
-1332000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2824000
CY2020 us-gaap Profit Loss
ProfitLoss
-33809000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17202000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17202000
CY2021 jagx Stock Issued During Period Value Extinguishment Of Convertible Securities
StockIssuedDuringPeriodValueExtinguishmentOfConvertibleSecurities
2516000
CY2021 jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
2982000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2021 jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
16000
CY2021 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
247000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3974000
CY2021 us-gaap Profit Loss
ProfitLoss
-52600000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11853000
CY2021 us-gaap Profit Loss
ProfitLoss
-52600000
CY2020 us-gaap Profit Loss
ProfitLoss
-33809000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5171000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2670000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3974000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
653000
CY2020 jagx Inducement Expense
InducementExpense
1647000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
796000
CY2020 jagx Proceeds From Cost Associated With Issuance Of Common Stock Through Stock Purchase Agreement
ProceedsFromCostAssociatedWithIssuanceOfCommonStockThroughStockPurchaseAgreement
1281000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2824000
CY2021 jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
-1953000
CY2020 jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
-2696000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1719000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1727000
CY2021 jagx Warrants Issued As Inducement To Exercise Equity Classified Warrants
WarrantsIssuedAsInducementToExerciseEquityClassifiedWarrants
1462000
CY2020 jagx Warrants Issued As Inducement To Exercise Equity Classified Warrants
WarrantsIssuedAsInducementToExerciseEquityClassifiedWarrants
3696000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1864000
CY2021 jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
94000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
553000
CY2021 jagx Derecognition Of Debt Discount
DerecognitionOfDebtDiscount
49000
CY2021 jagx Common Stock Issued In Exchange Of Services Rendered
CommonStockIssuedInExchangeOfServicesRendered
16000
CY2020 jagx Common Stock Issued In Exchange Of Services Rendered
CommonStockIssuedInExchangeOfServicesRendered
984000
CY2020 jagx Common Stock And Warrants Issued
CommonStockAndWarrantsIssued
76000
CY2020 jagx Non Cash Consideration Paid Up On Acquisition Of Business Issuance Of Equity
NonCashConsiderationPaidUpOnAcquisitionOfBusinessIssuanceOfEquity
33000
CY2020 jagx Loss On Recourse Obligation On Secured Borrowing
LossOnRecourseObligationOnSecuredBorrowing
-15000
CY2020 jagx Interest Paid On Conversion Of Debt To Equity
InterestPaidOnConversionOfDebtToEquity
-611000
CY2020 jagx Non Cash Expenditure For Settlement Of Trial Delay Fee
NonCashExpenditureForSettlementOfTrialDelayFee
612000
CY2020 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
1904000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2823000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2840000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
407000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
26000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2118000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
955000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
408000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-893000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
158000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-743000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3034000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1194000
CY2021 jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-19000
CY2020 jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-337000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34970000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15278000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2021 jagx Proceeds From Issuance Of Common Stock Through Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockThroughStockPurchaseAgreement
23232000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10975000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
12300000
CY2021 jagx Proceeds From Cost Associated With Issuance Of Common Stock Through Stock Purchase Agreement
ProceedsFromCostAssociatedWithIssuanceOfCommonStockThroughStockPurchaseAgreement
8595000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8961000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19492000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1776000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6057000
CY2021 jagx Umbrella Insurance Financing
UmbrellaInsuranceFinancing
1183000
CY2020 jagx Umbrella Insurance Financing
UmbrellaInsuranceFinancing
776000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1087000
CY2021 jagx Repayment Of Receivables Secured Borrowing
RepaymentOfReceivablesSecuredBorrowing
1822000
CY2020 jagx Repayment Of Receivables Secured Borrowing
RepaymentOfReceivablesSecuredBorrowing
6207000
CY2021 jagx Proceeds From Issuance Of Convertible Preferred Stock In Private Investment In Public Entities
ProceedsFromIssuanceOfConvertiblePreferredStockInPrivateInvestmentInPublicEntities
1751000
CY2020 jagx Proceeds From Issuance Of Convertible Preferred Stock In Private Investment In Public Entities
ProceedsFromIssuanceOfConvertiblePreferredStockInPrivateInvestmentInPublicEntities
668000
CY2021 jagx Repayment Of Insurance Premium Fee Classified As Financing Activity
RepaymentOfInsurancePremiumFeeClassifiedAsFinancingActivity
943000
CY2020 jagx Repayment Of Insurance Premium Fee Classified As Financing Activity
RepaymentOfInsurancePremiumFeeClassifiedAsFinancingActivity
681000
CY2021 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
247000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
100000
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
406000
CY2021 jagx Payment Of Equity Line Of Credit Warrant Offering Cost
PaymentOfEquityLineOfCreditWarrantOfferingCost
35000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
640000
CY2020 jagx Proceeds From Sale Of Finance Receivable
ProceedsFromSaleOfFinanceReceivable
7057000
CY2020 jagx Payments Of Warrant Issuance Costs
PaymentsOfWarrantIssuanceCosts
-185000
CY2020 jagx Payments Of Deferred Offering Cost
PaymentsOfDeferredOfferingCost
142000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43937000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4207000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8090000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3883000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17051000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8090000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
28000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
757000
CY2021 jagx Shares Issued In Extinguishment Of Exchange Note
SharesIssuedInExtinguishmentOfExchangeNote
2982000
CY2021 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
91000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
13000
CY2020 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
11227000
CY2020 jagx Common Stock Issued For Redemption Of Perpetual Preferred Stock
CommonStockIssuedForRedemptionOfPerpetualPreferredStock
6575000
CY2020 jagx Business Combination Consideration Common Stock Issued In Relation To Redemption Of Notes Payable And Related Interest
BusinessCombinationConsiderationCommonStockIssuedInRelationToRedemptionOfNotesPayableAndRelatedInterest
6165000
CY2020 jagx Shares Issued For Payments Of Contracted Research Fees
SharesIssuedForPaymentsOfContractedResearchFees
437000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219500000
CY2021 us-gaap Revenue Practical Expedient Initial Application And Transition Nondisclosure Of Transaction Price Allocation To Remaining Performance Obligation
RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation
true
CY2021 jagx Number Of Contracts
NumberOfContracts
2
CY2021Q4 jagx Number Of Specialty Pharmacies
NumberOfSpecialtyPharmacies
2
CY2021 jagx Number Of Portfolio Of Contract
NumberOfPortfolioOfContract
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Univers (W1)';font-size:8pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its financial statements and the accompanying notes. The accounting policies that reflect the Company’s more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are the valuation of stock options, valuation of Series C Perpetual Preferred Stock and Series D Perpetual Stock, valuation of hybrid instruments designated at fair value option (“FVO”), valuation of warrant liability, acquired in-process research and development (“IPR&amp;D”), useful lives assigned to long-lived assets, impairment assessment of intangible assets, valuation adjustments for excess and obsolete inventory, allowance for doubtful accounts, deferred taxes and valuation allowances on deferred tax assets, evaluation and measurement of contingencies, and recognition of revenue, including estimates for product returns. Those estimates could change, and as a result, actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, the World Health Organization declared the COVID-19 outbreak to be a pandemic. During the year ended December 31, 2021, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it. For a discussion of risks of COVID-19 relating to the Company’s business, see “Item 1A. - Risk Factors- Risks Related to Our Business- The novel coronavirus global pandemic could adversely impact our business, including our supply chain, clinical trials and commercialization of Mytesi and Canalevia.”</p>
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
21000
CY2021Q4 jagx Monthly Base Rent
MonthlyBaseRent
21000
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021 jagx Modifications To Liability Classified Instruments
ModificationsToLiabilityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Liability-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accounting for debt modifications and exchange transactions, it is the Company’s policy to first determine whether it qualifies as a Troubled Debt Restructuring (“TDR”) pursuant to the guidance provided in ASC 470-60. A debt modification or exchange transaction that is not within the scope of the ASC 470-60 is accounted for under ASC 470-50 to determine if the transaction is a mere modification or an extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company amended the terms of its October 2020 Purchase Agreement and Exchange Note 2 in the year 2021 (see Note 8). The Company also amended the terms of its Exchange Note 1, Exchange Note 2, March 2020 Purchase Agreement, and Series D Perpetual Preferred Stock in the year 2020 (see Note 8).</p>
CY2021 jagx Modifications To Equity Classified Instruments
ModificationsToEquityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Equity-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accounting for modifications of equity-classified warrants, it is the Company’s policy to determine the impact by analogy to the share-based compensation guidance of ASC 718, <i style="font-style:italic;">Compensation - Stock Compensation</i> (“ASC 718”). The model for a modified share-based payment award that is classified as equity and remains classified in equity after the modification is addressed in ASC 718-20-35-3. Pursuant to that guidance, the incremental fair value from the modification is recognized as an expense in the statements of operations to the extent the modified instrument has a higher fair value; however, in certain circumstances, such as when an entire class of warrants are modified, the measured increase in fair value may be more appropriately recorded as a deemed dividend, depending upon the nature of the warrant modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company modified certain equity-classified warrants in the year 2020 (see Note 9). The Company did not modify any equity-classified warrants in the year 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accounting for amendments to equity-classified preferred stock, it is the Company’s policy to measure the impact by analogy to ASC 470-50 in determining if such an amendment is an extinguishment or a modification. If the amendment results in an extinguishment, the Company follows the SEC staff guidance in ASC 260-10-S99-2 and ASC 470-20. If the amendment results in a modification, the Company follows the model in either ASC 718 or ASC 470-50, depending on the nature of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company modified the terms of its Series B Convertible Preferred Stock and Series C Perpetual Preferred Stock in the year 2020 (see Note 10). The Company did not modify any equity-classified preferred stock in the year 2021.</p>
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reclassification of Prior Year Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain prior period amounts of cash flows from financing activities in the consolidated statements of cash flows have been reclassified within the same category of cash flow activity to be consistent with the current period presentation. There were no reclassifications to other categories of cash flow activity and the reclassification did not impact the profit or loss during the prior period.</p>
CY2021Q4 us-gaap Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
0.99
CY2021Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
1000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
7819000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
463000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
518000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
534000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
89000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1604000
CY2021Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
7818000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6000000
CY2021Q4 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
1818000
CY2018Q3 jagx Letter Of Credit Received As Collateral
LetterOfCreditReceivedAsCollateral
475000
CY2018Q3 jagx Letter Of Credit Received As Collateral
LetterOfCreditReceivedAsCollateral
475000
CY2018Q3 jagx Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9580
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1084000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
240000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
919000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1159000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M15D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.2110
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
105260000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
357079000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1100000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
91243
CY2020 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
70000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
120000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
43000
CY2021Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
58000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
57000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
445000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1159000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
240000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
919000
CY2017Q3 jagx Percentage Of Amount Received To Be Paid To Glenmark
PercentageOfAmountReceivedToBePaidToGlenmark
0.25
CY2017Q3 jagx Maximum Amount To Be Received By Glenmark
MaximumAmountToBeReceivedByGlenmark
7000000.0
CY2021 jagx Payments Made To Date To Glenmark
PaymentsMadeToDateToGlenmark
2000000.0
CY2020 jagx Payments Made To Date To Glenmark
PaymentsMadeToDateToGlenmark
0
CY2019Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
2600000
CY2021Q2 us-gaap Unusual Or Infrequent Item Insurance Proceeds
UnusualOrInfrequentItemInsuranceProceeds
0
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1248000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1321000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2760000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1026000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
892000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
435000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4900000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2782000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
948000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
942000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
298000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
265000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677000
CY2021 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
33000
CY2020 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
40000
CY2021Q4 jagx Accrued Consulting Current
AccruedConsultingCurrent
47000
CY2020Q4 jagx Accrued Consulting Current
AccruedConsultingCurrent
31000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1687000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1687000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1687000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
22651000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24337000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1700000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1700000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1687000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1687000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
9416000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17851000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3456000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
696000
CY2021Q4 jagx Accrued Legal Costs
AccruedLegalCosts
414000
CY2020Q4 jagx Accrued Legal Costs
AccruedLegalCosts
291000
CY2021Q4 jagx Accrued Chargebacks And Discounts
AccruedChargebacksAndDiscounts
335000
CY2020Q4 jagx Accrued Chargebacks And Discounts
AccruedChargebacksAndDiscounts
736000
CY2021Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
285000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
281000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
277000
CY2021Q4 jagx Accrued Distributor Services Fees
AccruedDistributorServicesFees
250000
CY2020Q4 jagx Accrued Distributor Services Fees
AccruedDistributorServicesFees
1314000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
167000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1704000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
978000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7117000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4493000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
753000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2401818
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6473964
CY2021 jagx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
168750
CY2020 jagx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
7349426
CY2021 jagx Class Of Warrant Or Right Exercises
ClassOfWarrantOrRightExercises
-2007117
CY2020 jagx Class Of Warrant Or Right Exercises
ClassOfWarrantOrRightExercises
-11421464
CY2020 jagx Class Of Warrant Or Right Subject To Expire
ClassOfWarrantOrRightSubjectToExpire
108
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
563451
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2401818
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1021165
CY2020Q3 jagx Carrying Amount In Excess Of Fair Value Amount New Instruments
CarryingAmountInExcessOfFairValueAmountNewInstruments
150000
CY2019Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
166
CY2020Q4 jagx Carrying Amount In Excess Of Fair Value Amount New Instruments
CarryingAmountInExcessOfFairValueAmountNewInstruments
2500000
CY2021 jagx Schedule Of Common Stock Reserved For Future Issuance
ScheduleOfCommonStockReservedForFutureIssuance
<p style="font-family:'Arial Unicode MS';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,348,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,485,518</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inducement options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 154,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,289</p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options available for grant under stock option plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 631,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 198,866</p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock unit awards issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 487,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,871</p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 563,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,401,818</p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,185,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,126,362</p></td></tr></table>
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2348199
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1485518
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
631270
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
198866
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
487456
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1871
CY2021Q4 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
563451
CY2020Q4 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
2401818
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4185269
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4126362
CY2021 jagx Common Stock Voting Rights Number
CommonStockVotingRightsNumber
1
CY2020Q1 us-gaap Share Price
SharePrice
1.31
CY2021Q4 us-gaap Minority Interest
MinorityInterest
242000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.06
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.20
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
695995
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
483021
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.49
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.97
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3974000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2824000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52595000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38648000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44711588
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12880868
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.00
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3553999
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3927496
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28701463
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4600000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020Q4 jagx Deferred Tax Liabilities Fixed Assets And Intangibles
DeferredTaxLiabilitiesFixedAssetsAndIntangibles
3534000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4140000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3534000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1400000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 jagx Effective Income Tax Rate Reconciliation Intercompany Transactions
EffectiveIncomeTaxRateReconciliationIntercompanyTransactions
0.155
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.030
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.134
CY2021 jagx Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrant
0.007
CY2021 jagx Effective Income Tax Rate Reconciliation Book Loss On Debt Extinguishment
EffectiveIncomeTaxRateReconciliationBookLossOnDebtExtinguishment
0.003
CY2020 jagx Effective Income Tax Rate Reconciliation Book Loss On Debt Extinguishment
EffectiveIncomeTaxRateReconciliationBookLossOnDebtExtinguishment
0.042
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.018
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.034
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21153000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19863000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
241000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
241000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2161000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1711000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
450000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
156000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24005000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21971000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19865000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18437000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4140000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3534000
CY2021Q4 us-gaap Deferred Tax And Other Liabilities Noncurrent
DeferredTaxAndOtherLiabilitiesNoncurrent
678000
CY2021Q4 jagx Deferred Tax Liabilities Fixed Assets And Intangibles
DeferredTaxLiabilitiesFixedAssetsAndIntangibles
3462000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
77000
CY2021 jagx Unrecognized Tax Benefit Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitDecreasesResultingFromPriorPeriodTaxPositions
0
CY2020 jagx Unrecognized Tax Benefit Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitDecreasesResultingFromPriorPeriodTaxPositions
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
77000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
77000
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
77000
CY2021 us-gaap Profit Loss
ProfitLoss
-52600000
CY2020 us-gaap Profit Loss
ProfitLoss
-33809000

Files In Submission

Name View Source Status
0001558370-22-003435-index-headers.html Edgar Link pending
0001558370-22-003435-index.html Edgar Link pending
0001558370-22-003435.txt Edgar Link pending
0001558370-22-003435-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
jagx-20211231.xsd Edgar Link pending
jagx-20211231x10k.htm Edgar Link pending
jagx-20211231x10k003.jpg Edgar Link pending
jagx-20211231x10k_htm.xml Edgar Link completed
jagx-20211231xex21d1.htm Edgar Link pending
jagx-20211231xex23d1.htm Edgar Link pending
jagx-20211231xex23d1001.jpg Edgar Link pending
jagx-20211231xex23d2.htm Edgar Link pending
jagx-20211231xex31d1.htm Edgar Link pending
jagx-20211231xex31d2.htm Edgar Link pending
jagx-20211231xex32d1.htm Edgar Link pending
jagx-20211231xex32d2.htm Edgar Link pending
jagx-20211231_cal.xml Edgar Link unprocessable
jagx-20211231_def.xml Edgar Link unprocessable
jagx-20211231_lab.xml Edgar Link unprocessable
jagx-20211231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending